Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials.
about
Glucocorticoids for decompensated heart failureGlucocorticoids for decompensated heart failureAdvanced therapies for end-stage heart failureAdvanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations.Short-term add-on therapy with angiotensin receptor blocker for end-stage inotrope-dependent heart failure patients: B-type natriuretic peptide reduction in a randomized clinical trialPathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity.Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock.Retraction. rhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: a meta-analysis.Year in review in Intensive Care Medicine 2012. II: Pneumonia and infection, sepsis, coagulation, hemodynamics, cardiovascular and microcirculation, critical care organization, imaging, ethics and legal issues.Levosimendan in critical illness: a literature review.Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit.Translating thyroid hormone effects into clinical practice: the relevance of thyroid hormone receptor α1 in cardiac repair.Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESCLong-term intravenous inotropes in low-output terminal heart failure?Early treatment with isoflurane attenuates left ventricular dysfunction and improves survival in experimental Takotsubo.New pharmacological approaches in heart failure therapy: developments and possibilities.Raf kinase inhibitor protein: lessons of a better way for β-adrenergic receptor activation in the heart.Impact of early haemodynamic goal-directed therapy in patients undergoing emergency surgery: an open prospective, randomised trial.Levosimendan improves exercise performance in patients with advanced chronic heart failure.Association between inotrope treatment and 90-day mortality in patients with septic shock.Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.Time to re-think the use of dobutamine in sepsis.The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure.Cardiac RKIP induces a beneficial β-adrenoceptor-dependent positive inotropy.The spectrum of cardiovascular effects of dobutamine - from healthy subjects to septic shock patients.Haemodynamic effects of levosimendan in advanced but stable chronic heart failure.Neuromuscular electrical stimulation improves exercise tolerance in patients with advanced heart failure on continuous intravenous inotropic support use—randomized controlled trial
P2860
Q24187674-28B28E2A-3C78-47D7-A259-1AEDACA42A99Q24202169-26FBFEEC-4E29-4968-9F34-A6B777FE8165Q26992073-8A97FD38-EDC0-412F-B187-8B187370BEE8Q30394479-5AD744AB-9B45-4419-A1D3-252131E1AA35Q33574805-B47757C9-0122-4342-AC18-5FD2FB3A1F26Q34396286-BA732E5D-1DA4-4FDB-9D3C-952E17101195Q36144228-9EE047E3-4208-4A1C-81B0-D0EA79459A9BQ36410248-19D09585-DC24-43E1-A3FA-40BD3143D3A6Q36627891-113FD0FF-1A1A-4B74-92BA-A013C32FF792Q38191912-2ED16907-3D7E-49A1-B262-B323A6AD4FC1Q38272554-CB9BED54-6117-48D9-84F9-4EACB42A80F6Q38287099-51706F93-D1FE-4DB9-9D7A-2FEF7B8E4FFEQ38383238-D03780AE-7917-49AC-8049-F4F3FF92BD99Q38540286-9640BB44-D3D4-4AE0-9F4C-4823C995E42DQ38676886-C38E8B98-8A9C-429E-B47A-2DFBD018980CQ38734731-DEB6E720-444A-48F7-9514-357D3FD9CE59Q38759087-84D48391-FDCF-4C1B-AB83-0F214D98CD4FQ38759494-FB83D768-A647-4C45-8D70-9803CE7D126AQ39263982-90D35023-71FA-4E41-93E0-9580FBEAF02EQ41103206-75587847-A0C4-4734-891A-2A18EEDD2EA8Q41226308-24C382DC-3BE6-49F2-BD2B-BE32AE9B83C6Q45075848-38CE07B1-8B0A-4E7E-AB0C-FED0AD5ED559Q46143451-F59A4267-D41A-41A9-9F89-CEA9AE79B552Q46413734-F1B54F3E-519B-4A0A-BB1D-83555D2B4DF2Q47158526-80FD0C0E-FA0A-40EA-9A98-9CD38CEBBE2FQ48118068-AA1EAF4F-7C8F-443B-B981-B697D0F33658Q49559013-3C9E3CE5-AB93-4CE6-8719-A2896944D390Q53707293-76B3C223-C46F-4BEA-A91F-A4E5DE633D94Q56796094-34199A8E-3181-43BC-BB38-911BB49340EB
P2860
Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dobutamine for patients with s ...... randomised controlled trials.
@en
Dobutamine for patients with s ...... randomised controlled trials.
@nl
type
label
Dobutamine for patients with s ...... randomised controlled trials.
@en
Dobutamine for patients with s ...... randomised controlled trials.
@nl
prefLabel
Dobutamine for patients with s ...... randomised controlled trials.
@en
Dobutamine for patients with s ...... randomised controlled trials.
@nl
P2093
P2860
P1476
Dobutamine for patients with s ...... randomised controlled trials.
@en
P2093
Anthony Delaney
Catherine L Tacon
John McCaffrey
P2860
P2888
P304
P356
10.1007/S00134-011-2435-6
P577
2011-12-08T00:00:00Z